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Survey database. The study population included individuals above 18 years of age, 
suffering from depression (ICD-9-CM: 296, 300, and 311). HRQOL was assessed 
using SF-12 physical component summary (PCS) and mental component sum-
mary (MCS) scores. The significant predictors of HRQOL were identified using a 
multiple logistic regression model. SAS version 9.1 (SAS institute, Cary, NC) was 
used for data analysis. RESULTS: 2971 individuals were identified with depression. 
Impairments in both the domains of HRQOL were found. Young adults (OR= 0.198, 
95%CI = 0.116-0.337) were significantly less likely of showing lower PCS scores as 
compared to older adults. Unemployed (OR= 2.5, 95%CI= 1.981-3.182), less edu-
cated (OR= 1.49, 95%CI = 1.20-1.84) and individuals reporting poor perceived health 
(OR= 1.62, 95%CI = 1.43-12.99) had significantly higher odds of showing lower PCS 
scores compared to employed, more educated individuals having a better perceived 
health . Furthermore, middle aged adults (OR= 2.41, 95%CI = 1.78-3.28), unemployed 
(OR= 1.38, 95%CI = 1.08-1.76),less educated(OR= 1.31, 95%CI = 1.07-1.62) and indi-
viduals showing poor mental health (OR= 3.1,95%CI= 2.27-4.24) and overall per-
ceived health (OR= 1.72,95%CI= 1.32-2.25)showed significantly lower MCS scores. 
This was observed in comparison to older, employed, more educated individuals 
reporting good overall health and mental health status. CONCLUSIONS: Socio-
demographically disadvantaged people and people reporting lower perceived health 
status are at greater risk of having a poor quality of life. The factors identified in 
this study should be further investigated to evaluate why such differences exist in 
quality of life of depressed individuals.
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OBJECTIVES: Eating disorders are psychological conditions characterized by dis-
turbed eating habits affecting approximately 30% of teen girls with significant 
effects on their health related quality of life (HRQL). The objective of this study 
was to compare and contrast psychometric properties of eating disorder specific 
HRQL instruments. METHODS: HRQL instruments were included in this review 
if they were available in English, and there was at least one publication citing 
psychometric properties. Study instruments were evaluated based on: conceptual 
model, versatility (type of disorder), practicality, depth (< 15%), reliability (internal 
consistency and test-retest), construct validity (convergent and divergent or con-
firmatory factor analysis), and responsiveness. RESULTS: Six instruments were 
identified: Eating disorder quality of life (EDQOL), eating disorder quality of life 
scale (EDQLS), health related quality of life in eating disorder and its abbrevi-
ated version (HeRQoLED v2), Quality of life for eating disorders (QOL ED), and 
eating disorder well-being scale (EDwell). All instruments were developed for 
self-administration, taking 5-15minutes to complete, designed for use in female 
teens/adults supported by construct validity data, with most scales supporting 
group- as opposed to individual- level decision making. Only HeRQoLEDv2 was 
developed for use in both genders. Lack of meeting study criteria may be attrib-
uted to missing data, e.g., test-retest reliability. None of the six instruments met 
all study criteria; however, EDQLS and HeRQoLEDv2 met almost all study cri-
teria. CONCLUSIONS: All eating disorder instruments reviewed were developed 
within the last 10 years with available data being inadequate to assess all scales. 
Similar to Tirico et al. (2000), in the present study EDQLS and HeRQoLEDv2 met 
most of the study criteria, in contrast, EDQOL was excluded from this list due to 
missing data, Study data supported individual level decision making only for the 
HeRQoLEDv2.
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OBJECTIVES: Few studies have measured the impact of antidepressant treatment 
on family functioning. The effect of vortioxetine and agomelatine on different 
domains of family functioning was measured using the Depression and Family 
Functioning Scale (DFFS), comprising 15 items, each rated from 0-4. METHODS: 
The DFFS was assessed in REVIVE, a randomized, double-blind study of adults 
with an inadequate response to antidepressant treatment for the current depres-
sive episode switched to vortioxetine or agomelatine (NCT01488071). Pre-specified 
analyses of patients with baseline and follow-up DFFS assessments were per-
formed using change from baseline to weeks 8 and 12, analyzed by mixed models 
for repeated measurements (MMRM). Descriptive statistics characterizing depres-
sive symptoms (Montgomery-Åsberg Depression Rating Scale; MADRS), function-
ing (Sheehan Disability Scale; SDS), and quality of life (QoL; EQ-5D) were stratified 
according to DFFS total score quartiles at baseline. RESULTS: The DFFS total score 
was ~29 at baseline. Vortioxetine (n= 189) was superior to agomelatine (n= 187) by 
2.9 (95% CI [-4.7 to -1.1]) points at week 8 (p< 0.01) and at week 12 by 2.5 (95% CI 
[-4.5 to -0.5; p< 0.05]) points. Improvements in the DFFS total score and items were 
observed from baseline to week 8 (-10.8±0.7 (vortioxetine) and -7.9±0.7 (agomela-
tine), with further improvement at week 12 (-13.5±0.8 (vortioxetine) and -11.0±0.8 
(agomelatine)). At baseline, the level of family functioning was associated with 
functional and QoL impairment and, to a lesser extent, depressive symptoms 
(SDS total= 14.66, 19.31, 20.25, 21.68; EQ-5D= 0.68, 0.58, 0.53, 0.44; MADRS= 26.97, 
28.83, 29.39, 29.67 in the first, second, third, and fourth DFFS quartiles, respec-
tively; p< 0.01). CONCLUSIONS: Vortioxetine was significantly superior to ago-
melatine in terms of change in DFFS total score at weeks 8 and 12. Depressed 
patients with impaired family functioning showed worse overall functioning and 
QoL, suggesting that attention should be given to family functioning of depressed 
patients.
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OBJECTIVES: A study was done at tertiary care hospital to find the clinical evalu-
ations with particular identification and quality of life in schizophrenia patients. 
Patients visiting the psychiatry clinic were screened for psychological problems 
using a standard questionnaire and patients with history of psychiatry problems 
over a period of years. METHODS: It was a possible observational study for 6 
months in a hospital. The study enrolled 150 in-patients and out-patients with 
Schizophrenia. Patients were included in the study who met addition criteria 
after obtaining their knowledgeable permission. Patient history, principal symp-
toms, physical examination and computed tomography scan information were 
taken as the pretreatment evaluation. Antipsychotic drugs (Chlorpromazine and 
Haloperidol) were used in the patients to find the clinical evaluations and qual-
ity of life was analyzed. RESULTS: A study was conducted to search the clini-
cal profile, patient behavioural symptoms of drugs used among schizophrenia 
patients. A major number of patients who visited the hospital were diagnosed 
with different psychotic disorders. Among patients who were diagnosed with 
schizophrenia, 52% were males and 48% were females. Major factors were found 
to be family history (43%), alcohol (15%), thyroid disorders (7%), family problems 
(7%), and post menopausal problems (1%). Symptoms shown by the patients were 
abnormal behaviour (75%), smiling to self (15%), talking to self (29%), hallucinations 
(39%), aggressive (25%), sleeplessness (42%). Most common people affected were 
between 20-25 age groups (23%). CONCLUSIONS: It was concluded that patients 
were better recovered through treatment using Chlorpromazine and Haloperidol. 
Electro convulsive therapy through supportive treatment was used to improve the 
quality of life of the patients.
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OBJECTIVES: Measure the impact of reduced copay intervention on medication usage, 
healthcare utilization and costs, and health status. METHODS: A self-insured global 
healthcare company followed 529 insured members with anxiety and/or depression 
to determine the impact of waived pharmacy copays for anxiety and depression 
medications. Primary outcome was pre-post change in medication possession ratio 
(MPR). Secondary outcomes included initiation of medication, healthcare utilization, 
medical/pharmacy costs, and percentage of generic medication. A repeated-measures 
multivariable model was utilized to measure intervention impact, adjusting for age, 
gender, number of prescriptions, and comorbidity index. RESULTS: Unadjusted analy-
sis showed the copay intervention group was significantly more likely to start a new 
medication (31.4% vs. 29.5%, p = 0.033) and more likely to fill a generic medication 
(85.1% vs. 80.5%, p < 0.0001), and had higher average MPR (65.4% vs. 60.7%, p = 0.004) 
than the control group. Healthcare utilization was similar pre-post intervention. 
Multivariable adjusted analysis revealed a 4.5% increase in MPR after the interven-
tion (95% CI 2.2% - 6.8%, p = 0.0002). CONCLUSIONS: Eliminating pharmacy copay 
for depression and/or anxiety medications was associated with increased medica-
tion initiation and adherence. This value-based benefit design could be expanded 
with additional follow-up to measure longer-term trends and with other medication 
classes to assess similar impact.
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OBJECTIVES: This metareview identifies the common elements associated with 
published behavioral health-physical health (BH-PH) collaboration/integration 
strategies for managing comorbid conditions. METHODS: PubMed, Cochrane 
Library, and the Academy (AHRQ) were searched using keywords “review” or “meta-
analysis” and any combination of: “collaboration,” “integrated,” “behavioral,” “men-
tal,” “primary care,” “general practice,” “depression,” “schizophrenia,” “bipolar,” 
“panic,” anxiety,” “alcohol,” and “substance abuse.” RESULTS: The search identi-
fied 110 systematic reviews and/or meta-analyses covering BH-PH collaboration/
integration strategies, referencing almost 3,000 studies. Most studies addressed 
integration of BH services into primary care (PC), primarily major depression (less 
frequently anxiety, somatization, alcohol and addiction disorders) in adults and/or 
elderly. Some described integration of BH services into outpatient and community 
settings—effective venues for strategies like diet and exercise—or PH services 
in BH settings. Provider integration strategies usually included a psychiatrist or 
clinical psychologist available for PC consultation, but also therapists, BH-trained 
clinical nurses, social workers, care managers, and/or community health workers. 
Integrated BH-PH care models achieved clinically meaningful improvements in 
depression- and anxiety-related primary and secondary outcomes. Recent indi-
vidual studies have also reported improvements in medical/clinical outcomes 
(e.g., HbA1c in TEAMcare study) and physical functioning. The extent of integra-
tion was not significantly associated with depression or anxiety outcomes. No 
best practices (e.g., colocation) have been definitively validated as significant 
predictors for promoting positive health outcomes; rather, successful strategies 
implement multifaceted, system-level interventions, including brief psychologi-
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representative community-dwelling Medicare beneficiaries < 65 were included 
(n= 10,384 person-years, weighted n= 30,086,849 person-years). Psychotropic pre-
scription utilization included self-reported antidepressants, antipsychotics, stim-
ulants, mood stabilizers, anxiolytics, hypnotics, and antimanic prescription use. 
Weighted annual trends in psychotropic prescription utilization were estimated. 
Repeated person-year data using generalized estimating equations multivariable 
models were used to identify factors associated with psychotropic prescription 
utilization. RESULTS: Annual prevalence of any psychotropic prescription utiliza-
tion among disabled Medicare beneficiaries < 65 increased from 53.4% to 57.9% in 
2002-2009, but the trend was not statistically significant (P= 0.36). Antidepressants 
(35.09%), hypnotics (20.16%), and anxiolytics (17.31%) were the top three therapeutic 
classes used in 2009. No significant trend in utilization was observed for any indi-
vidual therapeutic classes. Multivariable results showed that beneficiaries < 65 who 
were female, white, divorced, Medicare-Medicaid dual eligible, with higher educa-
tion and poorer health status, smoking, and having chronic and psychiatric condi-
tions were more likely to use any psychotropic prescriptions (all P< 0.05). Female 
and white beneficiaries were more likely to use all psychotropic therapeutic classes 
except for antipsychotics (females only) and stimulants/antimanics (whites only). 
Beneficiaries with poorer health status and chronic conditions were more likely to 
use antidepressants, anxiolytics, and hypnotics. Medicare-Medicaid dual enrollees 
were more likely to use antipsychotics (all P< 0.05). CONCLUSIONS: Psychotropic 
prescription utilization is prevalent among disabled Medicare beneficiaries < 65. 
Patterns of use vary by psychotropic therapeutic class. Future research needs to 
evaluate psychotropic prescription access and quality of use among this vulner-
able population.
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OBJECTIVES: The use of attention-deficit/hyperactivity disorder (ADHD) medi-
cations has been increasing among children, adolescents and adults but little 
is known about its usage pattern, and treatment adherence among distinct age 
groups in Canada. This study sought to characterize utilization patterns of ADHD 
drugs approved for use in Canada with a special focus on the non-stimulant drug, 
atomoxetine. METHODS: Prescription data and anonymized longitudinal patient 
level data from IMS Brogan were used. Descriptive statistics were used to charac-
terize drug utilization patterns from 2010-2014. Utilization trends were analyzed 
with respect to age, gender, concomitant medications and physician specialty 
of the prescribing physician. Adherence patterns for atomoxetine were meas-
ured by the medication possession ratio (MPR). RESULTS: IMS data indicate that 
the average annual prescription volume of all ADHD drugs in Canada have been 
increasing each year (35% increase from 2,795,226 in 2009 to 3,772,266 in 2013). 
Methylphenidate stimulants accounted for approximately 70% of all prescriptions, 
and children 6-12 years accounted for most of these prescriptions. Prescriptions 
of atomoxetine showed the same increasing trends; however females aged 19-65 
accounted for most of this increase. ADHD drug use declined during the summer 
months and in 2013, over 20% of children aged 13-18 years had at least one gap of 
more than 30 days between the end of one prescription of atomoxetine and the 
start of the next. In addition, 25-35% of this age group had an MPR of less than 
80%. CONCLUSIONS: ADHD drug utilization has been increasing over the last 5 
years in Canada. Children aged 6-12 years account for most of the prescriptions, 
and they are most likely to go on a “drug holiday”. Given that serious adverse 
reactions can be associated with ADHD drugs in some children, their clinical 
benefits should be continuously and closely monitored, and weighed against their 
potential risks.
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OBJECTIVES: MAOIs were first discovered in the 1950s and used to manage depres-
sion when few alternatives existed. MAOIs block tyramine catabolism, meaning 
patients consuming tyramine rich foods (e.g. cheeses, cured meats) risk increased 
release of noradrenaline, potentially leading to hypertensive crisis. While MAOIs still 
have some role in depression management, little is known about current clinical 
practice. This study aims to audit the usage of MAOIs from 2004-2013. METHODS: 
The THIN database was used to identify all patients prescribed irreversible MAOIs 
between 01/01/2004–31/12/2013. Dates of first MAOI prescription and first depression 
diagnosis were identified, along with age, social deprivation score and repeat MAOI 
prescriptions. RESULTS: 886 patients were prescribed MAOIs during 2004-2013, 44% 
of which were new prescriptions. Median age at first use was 53years (IQR 43-63), M:F 
ratio was 1:1.8 and 49% were in the 2 most affluent quintiles. The median time from 
first depression diagnosis to first MAOI prescription was 11.2years (IQR 4.3-21.1). 
From 2004-2013, MAOI usage decreased from 555 to 248 patients, with treatment 
initiation falling from 72 to 28 patients. Median age of treated patients increased 
from 63 to 68years and 4-8% had concurrent SSRI prescriptions. Median prescrip-
tion use was 8.8months (IQR 5.1-11.0) in each year, with per patient prescriptions 
ranging from 37 (IQR 20-69) to 54 (IQR 27-83). Median time on MAOI from 2004-2013 
was 1.7years (IQR 0.4-4.8). CONCLUSIONS: THIN is a representative sample of 6% 
of the UK population. This study projects an estimated 600 UK patients start MAOIs 
yearly, with numbers decreasing. Estimated UK MAOI usage has fallen from 9,000 to 
4,000 patients during 2004-2013. Records indicate that patients are receiving shorter, 
more frequent prescriptions. NICE guidelines confirm that MAOIs still have some 
role in depression management, although not defined. This is the first large study 
to audit changes in MAOI usage.
cal therapies (e.g., motivational interviewing). The effectiveness of BH screening 
in PC settings is related to the availability of adequate treatment and follow-up 
systems of care. CONCLUSIONS: Increasing evidence is available concerning the 
effectiveness of BH-PH integration/collaboration strategies in treating depressive 
and anxiety symptoms and medical/clinical outcomes. Improved stratification of 
BH-PH integration models will determine the relative success of different integra-
tion approaches. Additional studies are needed in adolescents and people with 
schizophrenia and bipolar disorder.
PMH56
tHe relationsHiP between PseudoePHedrine sales and clandestine 
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OBJECTIVES: The illicit production of methamphetamine from the precursor 
chemical pseudoephedrine (PSE) in clandestine laboratories poses a public health 
risk for our communities and a financial burden on law enforcement. Previous 
work has shown a strong relationship between PSE sales and clandestine labs 
in Kentucky. The purpose of this project is to extend the study to Illinois and 
Louisiana and refine the model by adding additional explanatory variables and 
control variables. METHODS: Regression models predicting clandestine metham-
phetamine lab incidents using 2011 to 2012 county-level data for Kentucky, Illinois 
and Louisiana were calculated. Explanatory factors include PSE sales (in grams), 
population density, percent of adults with a high school diploma and percent pop-
ulation unemployed. Data sources include the National Precursor Log Exchange 
(NPLEx), the National Clandestine Laboratory Seizure report data received from 
the Drug Enforcement Agency, Federal Bureau of Investigation Crime in the United 
States statistics and the Census Bureau American Community Survey. RESULTS: 
Results indicate a strong positive relationship between PSE sales and clandestine 
labs (p< 0.01). Counties with a more highly educated population (p< 0.05) on aver-
age have fewer lab while a more rural population on average is associated with 
greater number of labs (p< 0.05). Individually, sales of PSE are strongly correlated 
to labs in both Kentucky and Illinois, but not Louisiana. CONCLUSIONS: PSE sales 
have a strong relationship to clandestine labs. Counties with greater sales of PSE 
have a greater number of clandestine labs, controlling for counties with no labs 
reported. These findings are an important addition to our previous work provid-
ing evidence for a strong association between PSE sales and clandestine labs in 
multiple states over multiple years and have important policy implications as 
states struggle with policy options to reduce methamphetamine production in 
their communities.
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OBJECTIVES: To assess treatment patterns, patient characteristics, and out-
comes for respondents with depression who were prescribed benzodiazepines 
(BZDs). METHODS: Survey-eligible adults with ≥ 2 medical claims for depression 
from 6/1/2009-5/31/2010 in the HealthCore Integrated Research Database were 
invited to participate in this retrospective/prospective study. Consenting respond-
ents completed index and 6-month post-index surveys assessing depression, anxi-
ety, and other health measures. Respondents’ survey data were linked to 24 months 
of claims data. Respondents with and without BZD prescriptions ±6 months from 
index survey date were identified. Healthcare utilization and costs were assessed 
pre- and post-index survey date and compared across users and non-users using 
descriptive statistics. RESULTS: Of 970 respondents who completed both surveys, 
638 (66%) were prescribed BZDs and 332 (34%) were not. Respondents with and with-
out BZD prescriptions were similar. Mean age was 47.9 and 45.7 years, respectively. 
The majority of respondents were female, overweight/obese, married/cohabiting, 
and college educated. Respondents prescribed BZDs were more likely to have pre-
index diagnoses of double depression (10.8% vs. 6.6%, p= .0338), anxiety (90.4% vs. 
65.7%, p< .0001), and a higher mean Quan-Charlson Comorbidity Index score (0.7 
vs. 0.5, p= .0393) as well as higher depression, fatigue, pain, insomnia, and anxiety 
index survey scores. Tricyclic antidepressants, serotonin–norepinephrine reuptake 
inhibitors, and second-generation antipsychotic use were higher for respondents 
prescribed BZDs (all p< .05). Mental health-related resource utilization involving 
psychiatrist visits was significantly higher for respondents prescribed BZDs at base-
line and follow-up (all p< .05). Although total annual medical mental health–related 
costs were similar ($3, 492 vs. $3,054, p= .5229), pharmacy and psychiatrist visit 
costs were significantly greater for respondents prescribed BZDs CONCLUSIONS: 
A majority of respondents with depression also had anxiety and were prescribed 
BZDs. Results suggest that BZD use was associated with more pronounced comor-
bid conditions and symptoms of depression, as well as higher health care resource 
utilization and costs.
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OBJECTIVES: One-third of Medicare beneficiaries < 65, who are deemed eligible for 
Social Security Disability Insurance, are disabled due to a mental disorder. But psy-
chiatric services research targeting this population is limited. This study estimated 
annual trends in and identified factors associated with psychotropic prescription 
utilization among disabled Medicare beneficiaries < 65. METHODS: This serial cross-
sectional study used 2002-2009 Medicare Current Beneficiary Survey data. Nationally 
